for the ProtecT study group. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial (vol 15, pg 1109, 2014)

被引：0
|
作者：
Lane, J. A.
Donovan, J. L.
Davis, M.
机构：
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E475 / E475
页数：1
相关论文
共 26 条
  • [1] Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial
    Lane, J. Athene
    Donovan, Jenny L.
    Davis, Michael
    Walsh, Eleanor
    Dedman, Daniel
    Down, Liz
    Turner, Emma L.
    Mason, Malcolm D.
    Metcalfe, Chris
    Peters, Tim J.
    Neal, David E.
    Hamdy, Freddie C.
    LANCET ONCOLOGY, 2014, 15 (10): : 1109 - 1118
  • [2] Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
    Hamdy, Freddie C.
    Donovan, Jenny L.
    Lane, J. Athene
    Mason, Malcolm
    Metcalfe, Chris
    Holding, Peter
    Wade, Julia
    Noble, Sian
    Garfield, Kirsty
    Young, Grace
    Davis, Michael
    Peters, Tim J.
    Turner, Emma L.
    Martin, Richard M.
    Oxley, Jon
    Robinson, Mary
    Staffurth, John
    Walsh, Eleanor
    Blazeby, Jane
    Bryant, Richard
    Bollina, Prasad
    Catto, James
    Doble, Andrew
    Doherty, Alan
    Gillatt, David
    Gnanapragasam, Vincent
    Hughes, Owen
    Kockelbergh, Roger
    Kynaston, Howard
    Paul, Alan
    Paez, Edgar
    Powell, Philip
    Prescott, Stephen
    Rosario, Derek
    Rowe, Edward
    Neal, David
    HEALTH TECHNOLOGY ASSESSMENT, 2020, 24 (37) : 1 - +
  • [3] Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
    S. Sanghera
    S. Mohiuddin
    J. Coast
    K. Garfield
    S. Noble
    C. Metcalfe
    J. A. Lane
    E. L. Turner
    D. Neal
    F. C. Hamdy
    R. M. Martin
    J. L. Donovan
    BMC Cancer, 20
  • [4] Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
    Sanghera, S.
    Mohiuddin, S.
    Coast, J.
    Garfield, K.
    Noble, S.
    Metcalfe, C.
    Lane, J. A.
    Turner, E. L.
    Neal, D.
    Hamdy, F. C.
    Martin, R. M.
    Donovan, J. L.
    BMC CANCER, 2020, 20 (01)
  • [5] Radical retropubic prostatectomy versus external beam radiotherapy for localised prostate cancer: An interim report of a multicentre, prospective, phase III randomised study
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 204 - 204
  • [6] Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial (vol 19, pg 1504, 2018)
    Roach, M.
    Moughan, J.
    Lawton, C. A. F.
    LANCET ONCOLOGY, 2018, 19 (11): : E581 - E581
  • [7] Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
    Sargos, Paul
    Chabaud, Sylvie
    Latorzeff, Igor
    Magne, Nicolas
    Benyoucef, Ahmed
    Supiot, Stephane
    Pasquier, David
    Abdiche, Menouar Samar
    Gilliot, Olivier
    Graff-Cailleaud, Pierre
    Silva, Marlon
    Bergerot, Philippe
    Baumann, Pierre
    Belkacemi, Yazid
    Azria, David
    Brihoum, Meryein
    Soulie, Michel
    Richaud, Pierre
    LANCET ONCOLOGY, 2020, 21 (10): : 1341 - 1352
  • [8] Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
    Wade, Julia
    Donovan, Jenny
    Lane, Athene
    Davis, Michael
    Walsh, Eleanor
    Neal, David
    Turner, Emma
    Martin, Richard
    Metcalfe, Chris
    Peters, Tim
    Hamdy, Freddie
    Kockelbergh, Roger
    Catto, James
    Paul, Alan
    Holding, Peter
    Rosario, Derek
    Kynaston, Howard
    Rowe, Edward
    Hughes, Owen
    Bollina, Prasad
    Gillatt, David
    Doherty, Alan
    Gnanapragasam, Vincent J.
    Paez, Edgar
    BMJ OPEN, 2020, 10 (09): : e036024
  • [9] Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
    Ahlgren, Goran M.
    Flodgren, Per
    Tammela, Teuvo L. J.
    Kellokumpu-Lehtinen, Pirkko
    Borre, Michael
    Angelsen, Anders
    Iversen, Jon Reidar
    Sverrisdottir, Asgerdur
    Jonsson, Eirikur
    Sengelov, Lisa
    EUROPEAN UROLOGY, 2018, 73 (06) : 870 - 876
  • [10] Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol
    F. H. E. Staal
    J. Janssen
    C. L. Brouwer
    J. A. Langendijk
    K. Ng Wei Siang
    E. Schuit
    I. J. de Jong
    J. F. Verzijlbergen
    R. J. Smeenk
    S. Aluwini
    BMC Cancer, 22
123